Analysis by electron microscopy of several tumor biopsies from two BRAF-mutant melanoma patients enrolled in clinical trials for vemurafenib indicated a two- to six fold increase in autophagic vacuoles compared with baseline measurements. The gene discussed is BRAF; the disease is melanoma.